TeamDrive
RUS
Vladimir Gurdus

Vladimir Gurdus

Founding Partner, COO

Телефоны:

+7 495 545-39-12

Send message

Vladimir is the co-founder and member of the Board of Directors of Doctor Ryadom (a private network of medical clinics). He is also the CEO and founder partner of RMI Partners (venture capital investment company), which manages the healthcare projects, one of them - a venture capital fund RusnanoMedInvest (RMI). One of the main investment in the RMI portfolio is Russian innovation pharmaceutical company NovaMedica LLC.

Vladimir is one of the leader of the team, implementing a major pharmaceutical and medical project, the brainchild of its investors RUSNANO OJSC and the U.S. firm Domain Associates LLC. RusnanoMedInvest was founded to implement this project. RMI is the largest venture capital company in life sciences in Eastern Europe, focusing on innovative pharmaceutical projects backed by sustainable, cutting edge technologies. NovaMedica LLC is responsible for the localisation of the products and technologies in Russia. It was also founded to implement ambitious plans to create a new GMP-compliant production facility and facilitate the production of innovative drugs.

Before assuming a key role as one of the project’s leaders and founding Team Drive, from 2007 to 2009 Vladimir was President at Medsi Group (part of AFK Sistema) and played a key role in transforming it into the leading privately-held medical service provider. Previously he had played an active role in starting up the ROSNO insurance company. After becoming a leading player on the Russian insurance market, ROSNO was acquired by the world’s largest insurance company Allianz Holding.  From 1991 to 2007 he was First Deputy CEO of ROSNO, and also the COO and CEO of ROSNO Group subsidiaries, such as ROSNO-MS. In 2006, after the acquisition of ROSNO by Allianz, Vladimir was appointed CEO of Allianz ROSNO-Life.

He is also an investor and the founder of a number of successful start-ups in the medical, insurance and IT sectors.

Vladimir is a member of the Government Expert Council of the Russian Federation. This organisation was established to involve the business community in the preparation and implementation of the decisions of the Russian Government, and also to ensure public oversight over the work of the federal authorities. Members of the Council attend the meetings of the Russian government, government and interdepartmental commissions and committees, and perform expert reviews of the draft decisions of the Russian government and federal executive agencies and the results of implementation. As a member of the Expert Council Vladimir proactively tackles issues of developing the Russian healthcare and pharmaceutical sectors. He also co-chairs a joint working group of the Expert Council and the Ministry of Health, whose chief remit is to draft the development framework of a healthcare system and the provision of the medicines required by the Russian population drug.

Vladimir is a member of the Public Council under the Ministry of Health of the Russian Federation – a permanent consultative public health oversight body.

Vladimir graduated cum laude from I.M. Sechenov Moscow Medical Academy. He has a second degree in finance and economics at RosNOU. Vladimir is a Doctor of Medical Sciences and Professor.

Media Center

  • 23 November 2017

    Registration of medicines in EAEU will be performed online

    The Eurasian Economic Union (EAEU) is completing the development of a unified information system that will facilitate the registration of medicinal products by businesses in the common market and provide complete information about these drugs to consumers.

  • 23 November 2017

    Kaluga Pharmaceutical Cluster received silver certificate of Cluster Excellence

    In the period of October 24 – 26, 2017, the Association of Kaluga Pharmaceutical Cluster passed the procedure of the on-site audit conducted by the experts of the European Secretariat for Cluster Analysis. The procedure included the evaluation of the cluster management system and core activities  using 30 indicators in accordance with the methodology of the European Cluster Excellence Initiative. The assessment score of the Association of Kaluga Pharmaceutical Cluster performance for more than 70% of these indicators have significantly exceeded the required values. 

  • 22 November 2017

    After unexpected tie, Amsterdam wins ‘coin toss’ for new EMA HQ

    Well, that was unexpected. The EU’s third and final vote on the new location of the European Medicine Agency tied between Milan and Amsterdam, with Amsterdam winning the proverbial coin toss tie-breaker (EU officials drew the city’s name out of a bowl).

  • 22 November 2017

    With only 2 warnings in 2017, pharma's ad police hits historic low

    As the end of the year nears, the pharma industry can usually look back at FDA enforcement letters for insight into the agency's thinking and guidance on marketing communications. But this year, there’s not much to review.

Read more